1. Red-hot biotechs to take spotlight at ASH virtual meeting — Moderna's 3-month data raise hopes for COVID-19 vaccine durability — BioNTech founder vaults into world's 500 richest — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

A graphical view of DaVita Q3 Earnings Slump

Discussion in 'DaVita' started by anonymous, Nov 7, 2017 at 5:49 PM.

  1. anonymous

    anonymous Guest

    Non-cash goodwill and asset impairment charges in the DMG reportable segment hurt DaVita's Q3 2017 results. Total U.S. dialysis treatments for 3Q17 were 7.2 million. As of Sept. 30, 2017, DaVita provided dialysis services to a total of about 218,200 patients.

    Graphical view of results http://alphastreet.com/b4c3bb58